Ontology highlight
ABSTRACT:
SUBMITTER: Toren PJ
PROVIDER: S-EPMC4708177 | biostudies-literature | 2013 Sep
REPOSITORIES: biostudies-literature
Toren Paul J PJ Gleave Martin E ME
Translational andrology and urology 20130901 3
Castrate resistant prostate cancer (CRPC) remains a disease with significant morbidity and mortality. The recent approval of abiraterone and enzalutamide highlight the improvements which can be made targeting the androgen receptor (AR) axis. Nonetheless, resistance inevitably develops and there is continued interest in targeting alternate pathways which cause disease resistance and progression. Here, we review non-AR targets in CRPC, with an emphasis on novel agents now in development. This incl ...[more]